HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Lu, Mudan ^a   Yu, Shanshan ^a   Xu, Wei ^b   Gao, Bo ^a   Xiong, Sidong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTINUCLEAR ANTIBODY; AUTACOID; CYTOKINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ANIMAL; BLOOD; CASE CONTROL STUDY; CELL LINE; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; YOUNG ADULT;

EID: 84930959577     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/946748     Document Type: Article

References (70)

1. B. H. Hahn, "Antibodies to DNA," The New England Journal of Medicine, vol. 338, no. 19, pp. 1359-1368, 1998.
2. F. J. Barrat and R. L. Coffman, "Development of TLR inhibitors for the treatment of autoimmune diseases," Immunological Reviews, vol. 223, no. 1, pp. 271-283, 2008.
3. A. Rahman and D. A. Isenberg, "Systemic lupus erythematosus," The New England Journal of Medicine, vol. 358, no. 9, pp. 929-939, 2008.
4. C. Guiducci, M. Gong, Z. Xu et al., "TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus," Nature, vol. 465, no. 7300, pp. 937-941, 2010.
5. G. C. Tsokos, "Systemic lupus erythematosus,"The New England Journal of Medicine, vol. 365, no. 22, pp. 2110-2121, 2011.
6. I. Marai, Y. Levi, and Y. Shoenfeld, "Morbidity and mortality in systemic lupus erythematosus," Harefuah, vol. 140, no. 12, pp. 1177-1228, 2001.
7. R. Cervera, M. A. Khamashta, J. Font et al., "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and latemanifestations in a cohort of 1,000 patients," Medicine, vol. 82, no. 5, pp. 299-308, 2003.
8. A. T. Borchers, C. L. Keen, Y. Shoenfeld, and M. E. Gershwin, "Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus," Autoimmunity Reviews, vol. 3, no. 6, pp. 423-453, 2004.
9. M. Herrmann, R. E. Voll, and J. R. Kalden, "Etiopathogenesis of systemic lupus erythematosus," Immunology Today, vol. 21, no. 9, pp. 424-426, 2000.
10. K. Ohl and K. Tenbrock, "Inflammatory cytokines in systemic lupus erythematosus," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 432595, 14 pages, 2011.
11. C. P. J. Maury and A.-M. Teppo, "Tumor necrosis factor in the serum of patients with systemic lupus erythematosus," Arthritis & Rheumatism, vol. 32, no. 2, pp. 146-150, 1989.
12. D. Aderka, A. Wysenbeek, H. Engelmann et al., "Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus," Arthritis and Rheumatism, vol. 36, no. 8, pp. 1111-1120, 1993.
13. C. Meijer, V. Huysen, R. T. J. Smeenk, and A. J. G. Swaak, "Profiles of cytokines (TNFα and IL-6) and acute phase proteins (CRP and α1AG) related to the disease course in patients with systemic lupus erythematosus," Lupus, vol. 2, no. 6, pp. 359-365, 1993.
14. D. Malide, P. Russo, and M. Bendayan, "Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients," Human Pathology, vol. 26, no. 5, pp. 558-564, 1995.
15. A. Studnicka-Benke, G. Steiner, P. Petera, and J. S. Smolen, "Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus," British Journal of Rheumatology, vol. 35, no. 11, pp. 1067-1074, 1996.
16. C. Gabay, N. Cakir, F. Moral et al., "Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity," Journal of Rheumatology, vol. 24, no. 2, pp. 303-308, 1997.
17. M. Aringerl, E. Feierl, G. Steiner et al., "Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death," Lupus, vol. 11, no. 2, pp. 102-108, 2002.
18. L. Dridi, J. Tankovic, B. Burghoffer, F. Barbut, and J.-C. Petit, "gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile," Antimicrobial Agents and Chemotherapy, vol. 46, no. 11, pp. 3418-3421, 2002.
19. M. Aringer, W. B. Graninger, G. Steiner, and J. S. Smolen, "Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study," Arthritis and Rheumatism, vol. 50, no. 10, pp. 3161-3169, 2004.
20. C.-Y. Tsai, T.-H.Wu, C.-L. Yu, J.-Y. Lu, and Y.-Y. Tsai, "Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis," Nephron, vol. 85, no. 3, pp. 207-214, 2000.
21. I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi, and P. Rovere-Querini, "HMGB1: guiding immunity from within," Trends in Immunology, vol. 26, no. 7, pp. 381-387, 2005.
22. H. E. Harris and A. Raucci, "Alarmin(g) news about danger: workshop on innate danger signals and HMGB1," EMBO Reports, vol. 7, no. 8, pp. 774-778, 2006.
23. M. E. Bianchi, "DAMPs, PAMPs and alarmins: all we need to know about danger," Journal of Leukocyte Biology, vol. 81, no. 1, pp. 1-5, 2007.
24. L. Ulloa and D. Messmer, "High-mobility group box 1 (HMGB1) protein: friend and foe," Cytokine and Growth Factor Reviews, vol. 17, no. 3, pp. 189-201, 2006.
25. J. S. Park, D. Svetkauskaite, Q. He et al., "Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein," The Journal of Biological Chemistry, vol. 279, no. 9, pp. 7370-7377, 2004.
26. R. Kokkola, Å. Andersson, G. Mullins et al., "RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages," Scandinavian Journal of Immunology, vol. 61, no. 1, pp. 1-9, 2005.
27. J. Tian, A. M. Avalos, S.-Y. Mao et al., "Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE," Nature Immunology, vol. 8, no. 5, pp. 487-496, 2007.
28. H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., "A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11942-11947, 2010.
29. H. Naglova and M. Bucova, "HMGB1 and its physiological and pathological roles," Bratislavské Lekárske Listy, vol. 113, no. 3, pp. 163-171, 2012.
30. U. Andersson, H. Erlandsson-Harris, H. Yang, and K. J. Tracey, "HMGB1 as a DNA-binding cytokine," Journal of Leukocyte Biology, vol. 72, no. 6, pp. 1084-1091, 2002.
31. N. Taniguchi, K.-I. Kawahara, K. Yone et al., "High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine," Arthritis & Rheumatism, vol. 48, no. 4, pp. 971-981, 2003.
32. J. Li, H. Xie, T. Wen, H. Liu, W. Zhu, and X. Chen, "Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus," The Journal of Rheumatology, vol. 37, no. 4, pp. 766-775, 2010.
33. W. Zhang, W. Xu, and S. Xiong, "Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization," The Journal of Immunology, vol. 184, no. 11, pp. 6465-6478, 2010.
34. W. Zhang, W. Xu, and S. Xiong, "Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component," The Journal of Immunology, vol. 187, no. 4, pp. 1764-1777, 2011.
35. X. Chen, Z. Wen, W. Xu, and S. Xiong, "Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization," PLoS ONE, vol. 8, no. 6,Article ID e65542, 2013.
36. Y. Cai, W. Zhang, and S. Xiong, "Mannose-binding lectin blunts macrophage polarization and ameliorates lupus nephritis," PLoS ONE, vol. 8, no. 4, Article ID e62465, 2013.
37. Z. Wen, L. Xu, W. Xu, Z. Yin, X. Gao, and S. Xiong, "Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA," PLoS ONE, vol. 8, no. 3, Article ID e58161, 2013.
38. W. Zhang, Y. Cai, W. Xu, Z. Yin, X. Gao, and S. Xiong, "AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation," Journal of Clinical Immunology, vol. 33, no. 5, pp. 925-937, 2013.
39. W. Zhang, Q. Zhou, W. Xu et al., "DNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway," Journal of Biological Chemistry, vol. 288, no. 19, pp. 13534-13550, 2013.
40. H. Yanai, T. Ban, Z. Wang et al., "HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses," Nature, vol. 462, no. 7269, pp. 99-103, 2009.
41. L. Mollica, F. de Marchis, A. Spitaleri et al., "Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities," Chemistry and Biology, vol. 14, no. 4, pp. 431-441, 2007.
42. M. Ohnishi, H. Katsuki, C. Fukutomi et al., "HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats," Neuropharmacology, vol. 61, no. 5-6, pp. 975-980, 2011.
43. G. Gong, L.-B. Yuan, L. Hu et al., "Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1," Acta Pharmacologica Sinica, vol. 33,no. 1, pp. 11-18, 2012.
44. V. E. Kelley and J. B. Roths, "Increase in macrophage Ia expression in autoimmune mice: role of the ipr gene," The Journal of Immunology, vol. 129, no. 3, pp. 923-925, 1982.
45. R. D. Bloom, S. Florquin, G. G. Singer, D. C. Brennan, and V. R. Kelley, "Colony stimulating factor-1 in the induction of lupus nephritis," Kidney International, vol. 43, no. 5, pp. 1000-1009, 1993.
46. M. A. Yui, W. H. Brissette, D. C. Brennan, R. P. Wuthrich, and V. E. Rubin-Kelley, "Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice," The American Journal of Pathology, vol. 139, no. 2, pp. 255-261, 1991.
47. G. H. Tesch, S. Maifert, A. Schwarting, B. J. Rollins, and V. R. Kelley, "Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice," The Journal of Experimental Medicine, vol. 190, no. 12, pp. 1813-1824, 1999.
48. L. Schiffer, R. Bethunaickan, M. Ramanujam et al., "Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis," Journal of Immunology, vol. 180, no. 3, pp. 1938-1947, 2008.
49. J. Menke, W. A. Rabacal, K. T. Byrne et al., "Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis," Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2581-2592, 2009.
50. A. Aderem and R. J. Ulevitch, "Toll-like receptors in the induction of the innate immune response," Nature, vol. 406, no. 6797, pp. 782-787, 2000.
51. O. Takeuchi and S. Akira, "Toll-like receptors; their physiological role and signal transduction system," International Immunopharmacology, vol. 1, no. 4, pp. 625-635, 2001.
52. V. Urbonaviciute, B. G. Fürnrohr, S. Meister et al., "Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE," The Journal of Experimental Medicine, vol. 205, no. 13, pp. 3007-3018, 2008.
53. C. C. Mok, "Biomarkers for lupus nephritis: a critical appraisal," Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 638413, 11 pages, 2010.
54. M. Ek, K. Popovic, H. E. Harris, C. S. Nauclér, and M. Wahren-Herlenius, "Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren's syndrome," Arthritis & Rheumatism, vol. 54, no. 7, pp. 2289-2294, 2006.
55. T. Taira, W. Matsuyama, H. Mitsuyama et al., "Increased serum high mobility group box-1 level in Churg-Strauss syndrome," Clinical and Experimental Immunology, vol. 148, no. 2, pp. 241-247, 2007.
56. Z. Wen, L. Xu, X. Chen et al., "Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/MicroRNA-155 pathway,"The Journal of Immunology, vol. 190, no. 11, pp. 5411-5422, 2013.
57. J. Li, R. Kokkola, S. Tabibzadeh et al., "Structural basis for the proinflammatory cytokine activity of high mobility group box 1," Molecular Medicine, vol. 9, no. 1-2, pp. 37-45, 2003.
58. C.-Y. Ma, Y.-L. Jiao, J. Zhang et al., "Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus," Rheumatology International, vol. 32, no. 2, pp. 395-402, 2012.
59. A. Zickert, K. Palmblad, B. Sundelin et al., "Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis," Arthritis Research & Therapy, vol. 14, no. 1, article R36, 2012.
60. A. W. S. de Souza, J. Westra, J. Bijzet et al., "Is serum HMGB1 a biomarker in ANCA-associated vasculitis?" Arthritis Research and Therapy, vol. 15, no. 5, article R104, 2013.
61. D. Y. H. Yap and K. N. Lai, "The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside," Nephrology, vol. 18, no. 4, pp. 243-255, 2013.
62. K. N. Lai and D. Y. H. Yap, "Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances," Journal of Biomedicine and Biotechnology, vol. 2010, Article ID365083, 10 pages, 2010.
63. T. Hirano, "Interleukin 6 and its receptor: ten years later," International Reviews of Immunology, vol. 16, no. 3-4, pp. 249-284, 1998.
64. R. Herrera-Esparza, O. Barbosa-Cisneros, R. Villalobos-Hurtado, and E. Avalos-Díaz, "Renal expression of IL-6 and TNFα genes in lupus nephritis," Lupus, vol. 7, no. 3, pp. 154-158, 1998.
65. S. Jothy and R. J. Sawka, "Presence of monocytes in systemic lupus erythematosus-associated glomerulonephritis. Marker study and significance," Archives of Pathology and Laboratory Medicine, vol. 105, no. 11, pp. 590-593, 1981.
66. M. Kobayashi, A. Koyama, M. Narita, and H. Shigematsu, "Intraglomerular monocytes in human glomerulonephritis," Nephron, vol. 59, no. 4, pp. 580-585, 1991.
67. G. S. Hill, M. Delahousse, D. Nochy et al., "Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages," Kidney International, vol. 59, no. 1, pp. 304-316, 2001.
68. R. S. Green, E. L. Stone, M. Tenno, E. Lehtonen, M. G. Farquhar, and J. Marth, "Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis," Immunity, vol. 27, no. 2, pp. 308-320, 2007.
69. J. C. Paulson, "Innate immune response triggers lupus-like autoimmune disease," Cell, vol. 130, no. 4, pp. 589-591, 2007.
70. J. Hutcheson, J. C. Scatizzi, A. M. Siddiqui et al., "Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity," Immunity, vol. 28, no. 2, pp. 206-217, 2008.